Search Results - "Janne, P A"

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials by Goss, G., Tsai, C.-M., Shepherd, F.A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., Cantarini, M., Johnson, M., Mitsudomi, T., Jänne, P.A., Yang, J.C.-H.

“…Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients…”
Get full text

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer by Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M.J., Arcila, M.E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A.M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Jänne, P.A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I.I., Wolf, J., Wu, Y.L., Yang, S.R., Yang, J.C.H., Yatabe, Y., Pentheroudakis, G., Peters, S.

“…The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell…”
Get full text

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients by Cappuzzo, F., Jänne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., Varella-Garcia, M.

“…Background: MET amplification has been detected in ∼20% of non-small-cell lung cancer patients (NSCLC) with epidermal growth factor receptor (EGFR) mutations…”
Get full text

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells by Wang, J, Mikse, O, Liao, R G, Li, Y, Tan, L, Janne, P A, Gray, N S, Wong, K-k, Hammerman, P S

“…Somatic alterations of fibroblast growth factor receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are…”
Get full text

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study by Planchard, D., Feng, P.-H., Karaseva, N., Kim, S.-W., Kim, T.M., Lee, C.K., Poltoratskiy, A., Yanagitani, N., Marshall, R., Huang, X., Howarth, P., Jänne, P.A., Kobayashi, K.

“…The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib…”
Get full text

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells by Tanizaki, J, Okamoto, I, Takezawa, K, Sakai, K, Azuma, K, Kuwata, K, Yamaguchi, H, Hatashita, E, Nishio, K, Janne, P A, Nakagawa, K

“…Background: Although most non-small-cell lung cancer (NSCLC) patients with the echinoderm microtubule-associated protein-like 4 ( EML4 ) – anaplastic lymphoma…”
Get full text

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium by Li, B.T., Janku, F., Jung, B., Hou, C., Madwani, K., Alden, R., Razavi, P., Reis-Filho, J.S., Shen, R., Isbell, J.M., Blocker, A.W., Eattock, N., Gnerre, S., Satya, R.V., Xu, H., Zhao, C., Hall, M.P., Hu, Y., Sehnert, A.J., Brown, D., Ladanyi, M., Rudin, C.M., Hunkapiller, N., Feeney, N., Mills, G.B., Paweletz, C.P., Janne, P.A., Solit, D.B., Riely, G.J., Aravanis, A., Oxnard, G.R.

“…Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also…”
Get full text

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC by Ou, S.-H. I., Jänne, P.A., Bartlett, C.H., Tang, Y., Kim, D.-W., Otterson, G.A., Crinò, L., Selaru, P., Cohen, D.P., Clark, J.W., Riely, G.J.

“…Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We…”
Get full text

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation by Peters, S, Loi, S, André, F, Chandarlapaty, S, Felip, E, Finn, S P, Jänne, P A, Kerr, K M, Munzone, E, Passaro, A, Pérol, M, Smit, E F, Swanton, C, Viale, G, Stahel, R A

“…Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and…”
Get more information

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma by Boiarsky, D., Lydon, C.A., Chambers, E.S., Sholl, L.M., Nishino, M., Skoulidis, F., Heymach, J.V., Luo, J., Awad, M.M., Janne, P.A., Van Allen, E.M., Barbie, D.A., Vokes, N.I.

“…Prior studies characterized the association of molecular alterations with treatment-specific outcomes in KRAS-mutant (KRASMUT) lung adenocarcinoma (LUAD). Less…”
Get full text

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor by Ercan, D, Zejnullahu, K, Yonesaka, K, Xiao, Y, Capelletti, M, Rogers, A, Lifshits, E, Brown, A, Lee, C, Christensen, J G, Kwiatkowski, D J, Engelman, J A, Jänne, P A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers…”
Get full text

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib by Yonesaka, K, Hirotani, K, Kawakami, H, Takeda, M, Kaneda, H, Sakai, K, Okamoto, I, Nishio, K, Jänne, P A, Nakagawa, K

“…Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab…”
Get full text

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients by Cappuzzo, F, Varella-Garcia, M, Finocchiaro, G, Skokan, M, Gajapathy, S, Carnaghi, C, Rimassa, L, Rossi, E, Ligorio, C, Di Tommaso, L, Holmes, A J, Toschi, L, Tallini, G, Destro, A, Roncalli, M, Santoro, A, Jänne, P A

“…The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor fluorescence in situ hybridisation-positive ( EGFR FISH+) metastatic…”
Get full text

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer by Engelman, Jeffrey A, Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borrás, Ana M, Gale, Christopher-Michael, Naumov, George N, Yeap, Beow Y, Jarrell, Emily, Sun, Jason, Tracy, Sean, Zhao, Xiaojun, Heymach, John V, Johnson, Bruce E, Cantley, Lewis C, Jänne, Pasi A

“…EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been…”
Get full text

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer by Flores, L M, Kindelberger, D W, Ligon, A H, Capelletti, M, Fiorentino, M, Loda, M, Cibas, E S, Jänne, P A, Krop, I E

“…Background: Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but their usefulness has been…”
Get full text

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients by Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P.A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., Destro, A., Roncalli, M., Crino, L., Franklin, W. A., Santoro, A., Varella-Garcia, M.

“…Background: Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain…”
Get full text

Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC by Planchard, D., Janne, P.A., Yu, H.A., Moro-Sibilot, D., Goldberg, T., Gu, X., Li, J., McGill, J., Yu, C., Slosberg, E.

Get full text

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) by Stinchcombe, T.E., Janne, P.A., Wang, X., Bertino, E.M., Weiss, J.M., Bazhenova, L., Gu, L., Lau, C.J., Paweletz, C.P., Jaslowski, A.J., Gerstner, G.J., Baggstrom, M.Q., Graziano, S.L., Bearden, J., Vokes, E.E.

Get full text

Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer by Toschi, L, Cappuzzo, F, Jänne, PA

Get full text

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors by Kris, M.G., Camidge, D.R., Giaccone, G., Hida, T., Li, B.T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M.E., Goldberg, Z., Jänne, P.A.

“…HER2 mutations and amplifications have been identified as oncogenic drivers in lung cancers. Dacomitinib, an irreversible inhibitor of HER2, EGFR (HER1), and…”
Get full text